ICG 1

• Background:

  ICG001 selectively inhibits colon carcinoma cell lines (SW480 and HCT-116 cells) but not normal colonic epithelial cells (CCD-841Co) . It is also efficacious in the Min mouse and nude mouse xenograft models of colon cancer. ICG-001 is a potent inhibitor of GBM stem cells in culture. ICG001 selectively inhibits Wnt/beta-catenin/CREB binding protein (CBP) signaling to reverses pulmonary fibrosis and ameliorate experimental dermal fibrosis in experimental models. ICG001 is currently in clinical trials for colon cancer and leukemias.

• Description:

  ICG 1 is a small molecule inhibitor that targets Wnt/β-catenin pathway. It inhibits TCF/β-catenin mediated transcription by competing with β-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM. It can be used to specifically evaluate the role of CBP/beta-catenin association on WNT signaling and cell physiology.

• Purity:

  ≥ 98%

• Solubility:

  ≥ 27.43 mg/mL in DMSO; insoluble in H2O; ≥ 35.47 mg/mL in EtOH with ultrasonic. For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while.

• Molecular Formula:

  C33H32N4O4

• Shipping Conditions:

  Room Temperature (continental US) or Gel Packs

• Storage Conditions:

  Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.

• Calculated Molecular Weight:

  548.63 Da

• CAS Number:

  847591-62-2